Quarter
Charts

TRAVERE THERAPEUTICS, INC.

TVTX

CIK 0001438533 · Quarterly mode · latest period FY2025 (Q4) (ending 2025-12-31) · sourced from SEC EDGAR

At a glance · FY2025 (Q4)

Revenue
$130M
↑+73.4% +$55Mvs FY2024 (Q4)
Gross Profit
$127M
↑+76.0% +$55Mvs FY2024 (Q4)

Quality Score

Quality score

6-dimension fundamental snapshot · latest annual filed values · S&P 500 calibration

Average
58/100
  • Profitability
    0ROIC -57.1% (10% = solid, 20%+ = moat)
  • Liquidity
    100Current Ratio 2.74 (above 1.5 = solid)
  • Leverage
    0Insufficient data
  • Efficiency
    48Asset Turnover 0.82x (1.0+ = capital-efficient)
  • Growth
    100Revenue YoY +73.4% (10% = solid, 25%+ = elite)
  • Margin Trend
    100Op Margin 15.1% · trend +167.6pts (4Q avg vs prior 4Q)

Calibrated to S&P 500 medians. Each sub-score is computed from a single CFA-grade ratio (Profitability = ROIC, Liquidity = Current Ratio, Leverage = D/E, Efficiency = Asset Turnover, Growth = Revenue YoY, Margin Trend = 4Q operating-margin avg vs prior 4Q). Overall = simple mean.

DCF intrinsic value

DCF intrinsic value

two-stage Gordon model

Project TVTX's free cash flow forward, discount back at your hurdle rate, divide by diluted shares. Edit the assumptions to see how sensitive the intrinsic value is.

8%

Trailing CAGR unavailable; default 8%

10%

10% is a common all-equity benchmark for US large-caps

2.5%

Should be ≤ long-run GDP growth (~2.5% nominal)

5

5-year explicit projection + perpetuity terminal

Intrinsic value per share
$7.29
Total enterprise IV
$650M
Diluted shares
0.09B
Terminal PV
$471M (72% of total)
Year-5 FCF
$56M
YearProjected FCFDiscounted PV
+1$41M$37M
+2$44M$36M
+3$48M$36M
+4$51M$35M
+5$56M$34M
Terminal$759M$471M

DCF outputs are HIGHLY sensitive to growth + WACC assumptions. A 1pp WACC change can shift IV by 20%+. Use this as a sanity-check vs market price, not a target — and always cross-check the underlying FCF source (EDGAR cashflow statement, latest annual). Margin of safety convention: 30-50% discount to IV before buying.

Capital allocation · trailing 4 quarters

how the company spent its cash
Capex (TTM)
$293K
investment in PP&E
Stock buybacks (TTM)
—
share count reduction
Stock-based comp (TTM)
$45M
non-cash dilution

Balance sheet · 2025-12-31

latest filed snapshot
Total assets
$605M
everything owned
Total liabilities
$490M
everything owed
Stockholders' equity
$115M
shareholder claim
Net debt
$-47M
Net cash position ($47M)

Recent performance · 67 quarters

Revenue↑+73.4% +$55M
$130M
Net Income↑+146.9% +$81M
$26M
Free Cash Flow
$61M
Operating Margin↑+104.4pts
15.1%

Drill down

TVTX Sankey

See TRAVERE THERAPEUTICS, INC.'s revenue flow into every line item of the income statement and balance sheet — every dollar accounted for, with prior-period comparison.

Open Sankey

TVTX Charts

67 quarters of historical line items — Income, Cash Flow, Balance Sheet, plus margins. Click any chart for the trend dialog.

Open Charts

TVTX Key Metrics

EPS, BVPS, FCF/Share, ROE, ROA, ROIC, D/E, Current Ratio, Quick Ratio, Asset Turnover — 10 CFA-grade fundamentals derived from EDGAR data.

Open Key Metrics